Literature DB >> 35951045

Iron quantitative analysis of motor combined with bulbar region in M1 cortex may improve diagnosis performance in ALS.

Yifang Bao1,2, Yan Chen3, Sirong Piao1,2, Bin Hu1,2, Liqin Yang1,2, Haiqing Li1,2, Daoying Geng4,5, Yuxin Li6,7.   

Abstract

OBJECTIVES: To explore whether the combined analysis of motor and bulbar region of M1 on susceptibility-weighted imaging (SWI) can be a valid biomarker for amyotrophic lateral sclerosis (ALS).
METHODS: Thirty-two non-demented ALS patients and 35 age- and gender-matched healthy controls (HC) were retrospectively recruited. SWI and 3D-T1-MPRAGE images were obtained from all individuals using a 3.0-T MRI scan. The bilateral posterior band of M1 was manually delineated by three neuroradiologists on phase images and subdivided into the motor and bulbar regions. We compared the phase values in two groups and performed a stratification analysis (ALSFRS-R score, duration, disease progression rate, and onset). Receiver operating characteristic (ROC) curves were also constructed.
RESULTS: ALS group showed significantly increased phase values in M1 and the two subregions than the HC group, on the all and elderly level (p < 0.001, respectively). On all-age level comparison, negative correlations were found between phase values of M1 and clinical score and duration (p < 0.05, respectively). Similar associations were found in the motor region (p < 0.05, respectively). On both the total (p < 0.01) and elderly (p < 0.05) levels, there were positive relationships between disease progression rate and M1 phase values. In comparing ROC curves, the entire M1 showed the best diagnostic performance.
CONCLUSIONS: Combining motor and bulbar analyses as an integral M1 region on SWI can improve ALS diagnosis performance, especially in the elderly. The phase value could be a valuable biomarker for ALS evaluation. KEY POINTS: • Integrated analysis of the motor and bulbar as an entire M1 region on SWI can improve the diagnosis performance in ALS. • Quantitative analysis of iron deposition by SWI measurement helps the clinical evaluation, especially for the elderly patients. • Phase value, when combined with the disease progression rate, could be a valuable biomarker for ALS.
© 2022. The Author(s), under exclusive licence to European Society of Radiology.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Disease progression; Motor cortex; ROC curve; Susceptibility-weighted imaging

Year:  2022        PMID: 35951045     DOI: 10.1007/s00330-022-09045-2

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   7.034


  47 in total

Review 1.  Amyotrophic lateral sclerosis.

Authors:  Michael A van Es; Orla Hardiman; Adriano Chio; Ammar Al-Chalabi; R Jeroen Pasterkamp; Jan H Veldink; Leonard H van den Berg
Journal:  Lancet       Date:  2017-05-25       Impact factor: 79.321

Review 2.  Amyotrophic lateral sclerosis.

Authors:  Matthew C Kiernan; Steve Vucic; Benjamin C Cheah; Martin R Turner; Andrew Eisen; Orla Hardiman; James R Burrell; Margaret C Zoing
Journal:  Lancet       Date:  2011-02-04       Impact factor: 79.321

3.  Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging.

Authors:  H Oba; T Araki; K Ohtomo; S Monzawa; G Uchiyama; K Koizumi; Y Nogata; K Kachi; Z Shiozawa; M Kobayashi
Journal:  Radiology       Date:  1993-12       Impact factor: 11.105

4.  Dysregulation of iron protein expression in the G93A model of amyotrophic lateral sclerosis.

Authors:  M Hadzhieva; E Kirches; A Wilisch-Neumann; D Pachow; M Wallesch; P Schoenfeld; I Paege; S Vielhaber; S Petri; G Keilhoff; C Mawrin
Journal:  Neuroscience       Date:  2012-11-20       Impact factor: 3.590

5.  Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis?

Authors:  Caroline Moreau; Véronique Danel; Jean Christophe Devedjian; Guillaume Grolez; Kelly Timmerman; Charlotte Laloux; Maud Petrault; Flore Gouel; Aurélie Jonneaux; Mary Dutheil; Cédrick Lachaud; Renaud Lopes; Grégory Kuchcinski; Florent Auger; Maeva Kyheng; Alain Duhamel; Thierry Pérez; Pierre François Pradat; Hélène Blasco; Charlotte Veyrat-Durebex; Philippe Corcia; Patrick Oeckl; Markus Otto; Luc Dupuis; Guillaume Garçon; Luc Defebvre; Z Ioav Cabantchik; James Duce; Régis Bordet; David Devos
Journal:  Antioxid Redox Signal       Date:  2018-02-08       Impact factor: 8.401

6.  Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS: correlating 7 tesla MRI and pathology.

Authors:  Justin Y Kwan; Suh Young Jeong; Peter Van Gelderen; Han-Xiang Deng; Martha M Quezado; Laura E Danielian; John A Butman; Lingye Chen; Elham Bayat; James Russell; Teepu Siddique; Jeff H Duyn; Tracey A Rouault; Mary Kay Floeter
Journal:  PLoS One       Date:  2012-04-17       Impact factor: 3.240

Review 7.  The Relevancy of Data Regarding the Metabolism of Iron to Our Understanding of Deregulated Mechanisms in ALS; Hypotheses and Pitfalls.

Authors:  Camille Petillon; Rudolf Hergesheimer; Hervé Puy; Philippe Corcia; Patrick Vourc'h; Christian Andres; Zoubida Karim; Hélène Blasco
Journal:  Front Neurosci       Date:  2019-01-15       Impact factor: 4.677

Review 8.  Epidemiology of amyotrophic lateral sclerosis: an update of recent literature.

Authors:  Elisa Longinetti; Fang Fang
Journal:  Curr Opin Neurol       Date:  2019-10       Impact factor: 5.710

Review 9.  Improving clinical trial outcomes in amyotrophic lateral sclerosis.

Authors:  Matthew C Kiernan; Steve Vucic; Kevin Talbot; Christopher J McDermott; Orla Hardiman; Jeremy M Shefner; Ammar Al-Chalabi; William Huynh; Merit Cudkowicz; Paul Talman; Leonard H Van den Berg; Thanuja Dharmadasa; Paul Wicks; Claire Reilly; Martin R Turner
Journal:  Nat Rev Neurol       Date:  2020-12-18       Impact factor: 42.937

Review 10.  Cortical Circuit Dysfunction as a Potential Driver of Amyotrophic Lateral Sclerosis.

Authors:  Aurore Brunet; Geoffrey Stuart-Lopez; Thibaut Burg; Jelena Scekic-Zahirovic; Caroline Rouaux
Journal:  Front Neurosci       Date:  2020-04-29       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.